Serum MG53 Biomarker for Tissue Damage Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of plasma membrane repair mechanisms is limited, and existing methods lack effective diagnostic tools for detecting tissue damage and monitoring therapeutic responses, particularly for muscle-related diseases.
Innovation Solution
Detection of MG53 in circulating blood as a biomarker for tissue damage, utilizing its varying levels to diagnose muscle-related disorders and monitor treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If MG53 detection is implemented as a diagnostic tool, then diagnostic capability for tissue damage is improved, but device complexity and implementation cost increase
Solution Approach 1:
The patent extracts MG53, a specific protein marker, from complex tissue damage diagnostic procedures. By focusing detection on this single extracted biomarker rather than comprehensive tissue analysis, the patent achieves precise diagnostic capability while simplifying the overall diagnostic approach. The MG53 protein is isolated and measured as a specific indicator of tissue injury, converting a complex diagnostic problem into a targeted measurement task.
2Reliability
If MG53 levels are monitored to track therapeutic response, then treatment monitoring capability is improved, but measurement frequency and time investment increase
Solution Approach 1:
The patent establishes baseline MG53 levels before treatment begins and sets predetermined monitoring intervals. By planning the monitoring schedule in advance and establishing reference values preliminarily, the patent enables efficient treatment tracking. Clinicians can compare subsequent MG53 measurements against the pre-established baseline to assess therapeutic response, reducing the time needed for evaluation at each monitoring point.
3Measurement precision
If MG53 is used as a biomarker for muscle-related diseases, then disease detection accuracy is improved, but specificity requirements and diagnostic complexity increase
Solution Approach 1:
The patent uses MG53 as an intermediary biomarker that indirectly indicates tissue damage and muscle-related diseases. Rather than directly detecting disease pathology, the MG53 protein serves as a measurable intermediary that correlates with tissue injury. This intermediary approach simplifies detection by focusing on a single protein marker that can be quantified through established laboratory techniques, bridging the gap between complex disease states and measurable parameters.
Data Source
AI summary
Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach.